Form 4: Hims & Hers CFO Sells Shares After Option Exercise

Hims & Hers Health, Inc.'s Chief Financial Officer, Oluyemi Okupe, exercised stock options and subsequently sold 11,581 shares of Class A Common Stock for approximately $48.05 per share.

Summary

• Oluyemi Okupe, Chief Financial Officer of Hims & Hers Health, Inc. (HIMS), exercised 11,581 stock options at an exercise price of $5.01 per share on August 13, 2025.
• Concurrently, Okupe sold 11,581 shares of Class A Common Stock at an average weighted price of $48.0459 per share, with prices ranging from $47.84 to $48.32.
• The transactions were conducted pursuant to a Rule 10b5-1 pre-arranged trading plan.
• Following these transactions, Okupe directly holds 116,806 shares of Class A Common Stock and indirectly holds 7,853 shares through the Oluyemi Okupe Separate Property Trust.
• A transfer of 62,722 shares from the Oluyemi Okupe Separate Property Trust to Okupe's direct holdings also occurred.
• Okupe retains 361,365 unexercised stock options.
• The exercised options had a vesting schedule of 25% on January 24, 2023 (12-month anniversary of January 24, 2022 Vesting Commencement Date), with the remainder vesting in 36 equal monthly installments thereafter, contingent on continuous service.

Sentiment

Score: 5

Explanation: The sentiment is largely neutral because the transaction is a routine insider disclosure of an option exercise and subsequent sale, often for liquidity or diversification purposes, especially given it's under a 10b5-1 plan. However, any insider sale, particularly by a CFO, can be viewed with slight caution by investors, even if pre-planned, as it reduces the executive's direct equity exposure. The significant profit from the option exercise ($48.0459 sale price vs $5.01 exercise price) is positive for the individual but doesn't directly impact company sentiment.

Positives

• The exercise of stock options indicates the value of the company's equity compensation and the executive's belief in the stock's value at the time of grant.
• The transactions were conducted under a Rule 10b5-1 plan, indicating a pre-scheduled sale not based on immediate, non-public information.

Negatives

• The sale of 11,581 shares by a key executive (CFO) could be perceived as a negative signal by some investors, even if part of a pre-arranged plan.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The sale of shares by a CFO could be interpreted differently by shareholders; some may view it as a routine liquidity event, while others might see it as a slight negative signal regarding future prospects, despite the 10b5-1 plan.

Key Dates

Recommendation

The filing is a routine insider transaction report (Form 4) detailing an option exercise and subsequent sale by the CFO. While the sale of shares by an executive can sometimes be perceived negatively, this transaction was conducted under a Rule 10b5-1 plan, indicating it was pre-scheduled and not based on immediate, non-public information. This type of filing typically does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. Therefore, a "hold" recommendation is appropriate as this filing alone does not present a compelling reason to buy or sell, but rather provides transparency on executive compensation management.

Keywords

Hims & Hers Health, HIMS, SEC Form 4, Insider Trading, Stock Options, Equity Compensation, CFO, Oluyemi Okupe, Rule 10b5-1, Share Sale